| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANO HEALTH Aktie jetzt für 0€ handeln | |||||
| 20.10.25 | Ex-Cano Health CEO on Trial Amid $72M Fraud Claims | 3 | MedCity News |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 244,30 | +0,25 % | Dividendenbekanntmachungen (09.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANSIX INC US00773T1016 0,16 USD 0,1377 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2496 EUR ALPHABET INC CDR CA02080K1049 0... ► Artikel lesen | |
| INTUITIVE SURGICAL | 426,50 | +0,34 % | Intuitive Surgical: Steht ein weiterer Rücksetzer bevor? | Die Intuitive-Surgical-Aktie zeigt seit dem Jahreswechsel eine deutlich schwächere Struktur. Rutscht der Kurs in Richtung der nächsten Unterstützung ab Den vollständigen Artikel lesen ... ► Artikel lesen | |
| THERMO FISHER | 439,25 | -0,03 % | Thermo Fisher Opens Bay Area Cryo-EM Drug Discovery Center | ||
| ROKU | 85,57 | -0,60 % | Is Roku Stock a Buy as Platform Revenues and ARPU Improve? | ||
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA 7300,B0Y,YAG: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZEROSTACK CORP.... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 37,245 | -0,15 % | Centene to reaffirm full-year earnings guidance | ||
| QUIDELORTHO | 16,900 | -1,17 % | QuidelOrtho präsentiert Wachstumsstrategie auf Raymond James Konferenz | ||
| VERU | 2,490 | 0,00 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| NANO-X IMAGING | 2,705 | 0,00 % | Nanox signs distribution deal for imaging system in Southeast U.S. | ||
| TEMPEST THERAPEUTICS | 2,385 | 0,00 % | Tempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 | 100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade - 3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression... ► Artikel lesen | |
| FULGENT GENETICS | 12,800 | -0,78 % | Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix | ||
| LANTHEUS | 69,44 | +0,96 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection | New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 4,380 | +6,31 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 17,500 | -1,69 % | AMN Healthcare Services Inc: AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results | Quarterly revenue of $748 million- GAAP loss of ($0.20)/share and adjusted EPS of $0.22DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen |